ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.

Amvuttra is the first and only RNA interference (RNAi) therapeutic approved by the EC for both the cardiomyopathy and the ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the European Commission (EC) to treat adults with ...

Biotechnology Innovation Organization trade show is expected to bring about 20,000 participants to Boston starting on Monday.

Our process uses bottom-up financial analysis aimed at identifying large-cap companies that we think have the potential to ...